Abstract
Synovial macrophages are crucial in the development of joint inflammation and bone damage; however, the pathways that control macrophage remodeling in inflammatory M1 cells or bone-eroding osteoclasts are not fully understood. We determined that elevated IL-7R/CD127 expression is the hallmark of rheumatoid arthritis (RA) M1 macrophages and that these cells are highly responsive to interleukin-7 (IL-7)-driven osteoclastogenesis. We established that lipopolysaccharide (LPS), interferon-γ (IFNγ), and tumor necrosis factor-α (TNFα), the classic M1 macrophage mediators, enhance IL-7R expression in RA and murine macrophages. The local expression of IL-7 provokes arthritis, predominantly through escalating the number of F480+iNOS+ cells rather than CD3+ T cells. Ectopic LPS injection stabilizes IL-7-induced arthritis by increasing myeloid IL-7R expression, in part via IFNγ induction. Hence, in RAG−/− mice, IL-7-mediated arthritis is suppressed because of the reduction in myeloid IL-7R expression due to the lack of IFNγ. Moreover, the amelioration of IL-7-induced arthritis by anti-TNF therapy is due to a decrease in the number of cells in the unique F480+iNOS+IL-7R+CCL5+ subset, with no impact on the F480+Arginase+ cell or CD3+ T cell frequency. Consistent with the preclinical findings, the findings of a phase 4 study performed with RA patients following 6 months of anti-TNF therapy revealed that IL-7R expression was reduced without affecting the levels of IL-7. This study shifts the paradigm by discovering that IL-7-induced arthritis is dependent on F480+iNOS+IL-7R+CCL5+ cell function, which activates TH-1 cells to amplify myeloid IL-7R expression and disease severity.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
SILAC-based quantitative proteomics to investigate the eicosanoid associated inflammatory response in activated macrophages
Journal of Inflammation Open Access 01 September 2022
-
In vitro responses to platelet-rich-plasma are associated with variable clinical outcomes in patients with knee osteoarthritis
Scientific Reports Open Access 01 June 2021
-
Epigenetic regulation of macrophages: from homeostasis maintenance to host defense
Cellular & Molecular Immunology Open Access 29 October 2019
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout








References
Bresnihan, B. Pathogenesis of joint damage in rheumatoid arthritis. J. Rheumatol. 26, 717–719 (1999).
Haringman, J. J. et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 64, 834–838 (2005).
Adamopoulos, I. E. et al. Synovial fluid macrophages are capable of osteoclast formation and resorption. J. Pathol. 208, 35–43 (2006).
Elshabrawy, H. A., Essani, A. E., Szekanecz, Z., Fox, D. A. & Shahrara, S. TLRs, future potential therapeutic targets for RA. Autoimmun. Rev. 16, 103–113 (2017).
Udalova, I. A., Mantovani, A. & Feldmann, M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nat. Rev. Rheumatol. 12, 472–485 (2016).
Ambarus, C. A., Noordenbos, T., de Hair, M. J., Tak, P. P. & Baeten, D. L. Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis. Arthritis Res. Ther. 14, R74 (2012).
Zhu, W. et al. Anti-citrullinated protein antibodies induce macrophage subset disequilibrium in RA patients. Inflammation 38, 2067–2075 (2015).
Li, J. et al. Inhibition of fucosylation reshapes inflammatory macrophages and suppresses type II collagen-induced arthritis. Arthritis Rheumatol. 66, 2368–2379 (2014).
Choi, Y., Arron, J. R. & Townsend, M. J. Promising bone-related therapeutic targets for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 543–548 (2009).
Gravallese, E. M. Bone destruction in arthritis. Ann. Rheum. Dis. 61(Suppl. 2), ii84–ii86 (2002).
Dimitroulas, T., Nikas, S. N., Trontzas, P. & Kitas, G. D. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun. Rev. 12, 958–966 (2013).
Pickens, S. R. et al. Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of rheumatoid arthritis. Arthritis Rheum. 63, 2884–2893 (2011).
Chen, Z. et al. The novel role of IL-7 ligation to IL-7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis. J. Immunol. 190, 5256–5266 (2013).
Hartgring, S. A. et al. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum. 62, 2716–2725 (2010).
Churchman, S. M. & Ponchel, F. Interleukin-7 in rheumatoid arthritis. Rheumatology (Oxf.). 47, 753–759 (2008).
Lee, C. K. et al. Generation of macrophages from early T progenitors in vitro. J. Immunol. 166, 5964–5969 (2001).
van Roon, J. A. et al. Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. Arthritis Rheum. 52, 1700–1710 (2005).
Standiford, T. J., Strieter, R. M., Allen, R. M., Burdick, M. D. & Kunkel, S. L. IL-7 up-regulates the expression of IL-8 from resting and stimulated human blood monocytes. J. Immunol. 149, 2035–2039 (1992).
Weitzmann, M. N., Cenci, S., Rifas, L., Brown, C. & Pacifici, R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood 96, 1873–1878 (2000).
Toraldo, G., Roggia, C., Qian, W. P., Pacifici, R. & Weitzmann, M. N. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl Acad. Sci. USA 100, 125–130 (2003).
Colucci, S. et al. Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J. Pathol. 212, 47–55 (2007).
Takano, H. et al. Comparison of the activities of multinucleated bone-resorbing giant cells derived from CD14-positive cells in the synovial fluids of rheumatoid arthritis and osteoarthritis patients. Rheumatoloy (Oxf.). 43, 435–441 (2004).
Hartgring, S. A., Willis, C. R., Bijlsma, J. W., Lafeber, F. P. & van Roon, J. A. Interleukin-7-aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation. Arthritis Res. Ther. 14, R137 (2012).
Hartgring, S. A. et al. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis Rheum. 60, 2595–2605 (2009).
van Roon, J. A. et al. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 664–669 (2007).
Arnett, F. C. et al. The American Rheumatism Association1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31, 315–324 (1988).
Pickens, S. R. et al. Characterization of CCL19 and CCL21 in rheumatoid arthritis. Arthritis Rheum. 63, 914–922 (2011).
Pickens, S. R. et al. Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization. Angiogenesis 14, 443–455 (2011).
Kim, S. J. et al. Ligation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis. J. Immunol. 193, 3902–3913 (2014).
Acknowledgements
This work was supported in part by awards from the Department of Veteran’s Affairs MERIT Award (1I01BX002286), the National Institutes of Health (AR056099 and AR065778), the UCB Investigator Initiated Award, and the National Psoriasis Foundation (NPF).
Author information
Authors and Affiliations
Contributions
All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. S.S. had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design: S.K. and S.S. Acquisition of data: S.K., M.V.V., K.P., S.U., K.V., R.Z., and S.S. Analysis and interpretation of data: S.K., H.C., K.P., S.U., K.V., J.C., M.M., D.F., and S.S. Providing reagents and involved in the phase 4 study: H.C., A.C., S.V., S.A., A.M., and N.S.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Kim, Sj., Chang, H.J., Volin, M.V. et al. Macrophages are the primary effector cells in IL-7-induced arthritis. Cell Mol Immunol 17, 728–740 (2020). https://doi.org/10.1038/s41423-019-0235-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41423-019-0235-z
This article is cited by
-
SILAC-based quantitative proteomics to investigate the eicosanoid associated inflammatory response in activated macrophages
Journal of Inflammation (2022)
-
Inhibition of IRAK4 dysregulates SARS-CoV-2 spike protein-induced macrophage inflammatory and glycolytic reprogramming
Cellular and Molecular Life Sciences (2022)
-
In vitro responses to platelet-rich-plasma are associated with variable clinical outcomes in patients with knee osteoarthritis
Scientific Reports (2021)
-
IRAK4 inhibition: a promising strategy for treating RA joint inflammation and bone erosion
Cellular & Molecular Immunology (2021)
-
Epigenetic regulation of macrophages: from homeostasis maintenance to host defense
Cellular & Molecular Immunology (2020)